KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Oscar Health (OSCR) Cash & Equivalents (2020 - 2025)

Oscar Health's Cash & Equivalents history spans 6 years, with the latest figure at $2.8 billion for Q4 2025.

  • For Q4 2025, Cash & Equivalents rose 81.65% year-over-year to $2.8 billion; the TTM value through Dec 2025 reached $2.8 billion, up 81.65%, while the annual FY2025 figure was $2.8 billion, 81.65% up from the prior year.
  • Cash & Equivalents reached $2.8 billion in Q4 2025 per OSCR's latest filing, up from $2.1 billion in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $2.8 billion in Q4 2025 to a low of $1.1 billion in Q3 2021.
  • Average Cash & Equivalents over 5 years is $1.9 billion, with a median of $2.1 billion recorded in 2022.
  • Peak YoY movement for Cash & Equivalents: skyrocketed 372.08% in 2021, then plummeted 33.75% in 2023.
  • A 5-year view of Cash & Equivalents shows it stood at $1.1 billion in 2021, then surged by 41.18% to $1.6 billion in 2022, then increased by 20.0% to $1.9 billion in 2023, then decreased by 18.35% to $1.5 billion in 2024, then surged by 81.65% to $2.8 billion in 2025.
  • Per Business Quant, the three most recent readings for OSCR's Cash & Equivalents are $2.8 billion (Q4 2025), $2.1 billion (Q3 2025), and $2.6 billion (Q2 2025).